<DOC>
	<DOCNO>NCT01285596</DOCNO>
	<brief_summary>Young elderly , male female subject give 2 different dos mirabegron 7 day . Levels mirabegron blood assess .</brief_summary>
	<brief_title>A Study Evaluate How Mirabegron Enters Leaves Bloodstream According Age Sex</brief_title>
	<detailed_description />
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Healthy elderly subject age 55 year OR Healthy young subject age 18 45 year , inclusive Male must agree sexual abstinence and/or use highly effective method birth control screen 3 month last dose study medication Female subject must nonchild bear potential , i.e . post menopausal , surgically sterilize ( e.g . tubal ligation ) , hysterectomy medical history , must practice adequate nonhormonal contraceptive method prevent pregnancy . Nonhormonal contraceptive method define : Sexual abstinence 1 month admission 3 month discharge , OR Subject 's sexual partner surgically sterilize ( since least 3 month prior screen ) , OR Subject two ( 2 ) follow contraceptive method : A ) Diaphragm spermicide ; B ) Intrauterine device ; C ) Sexual partner use condom combination spermicidal creamDuring study subject willing use 1 3 follow contraceptive method : diaphragm spermicide , intrauterine device partner use condom combination spermicidal cream Body Mass Index 18.5 30.0 kg/m2 , inclusive Known suspect hypersensitivity Mirabegron component formulation use Pregnant breast feeding within 6 month screen assessment Any liver function test ( i.e . ALT , AST Alkaline phosphatase ) upper limit normal repeat measurement Any clinically significant history asthma , eczema , allergic condition previous severe hypersensitivity drug ( exclude nonactive Hayfever ) Any clinically significant history disease disorder gastrointestinal , cardiovascular , respiratory , renal , hepatic , neurological , dermatological , psychiatric metabolic judge investigator Any clinically significant abnormality follow investigator 's review prestudy physical examination , ECG clinical laboratory test A hemoglobin value &lt; 13 g/dl ( 8.1 mmol/l ) males &lt; 12 g/dl ( 7.5 mmol/l ) females OR hematocrit value &lt; 40.0 % male &lt; 37 % female OR Red Blood Cell count &lt; 4.5 T/l ( 4500 mm3 ) males &lt; 3.8 T/l ( 3800 mm3 ) females screen and/or day admission clinical unit Abnormal pulse and/or blood pressure measurement prestudy visit follow : Pulse &lt; 40 &gt; 90 bpm ; mean systolic blood pressure &gt; 160 mmHg ( elderly ) &gt; 140 mmHg ( young ) ; mean diastolic blood pressure &gt; 100 mmHg ( elderly ) &gt; 90 mmHg ( young ) , blood pressure measurement take triplicate subject rest supine position 5 min ; pulse measure automatically A marked baseline prolongation QT/QTc interval repeat measurement &gt; 450 m , history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsades de pointes , structural heart disease , family history Long QT Syndrome ( LQTS ) Use prescribed OTC ( overthecounter ) drug ( include vitamin , natural herbal remedy , e.g . St. John 's wort ) 2 week prior admission Clinical Unit , except occasional use paracetamol ( 3 g/day ) Regular use inducer liver metabolism ( e.g . barbiturate , rifampin ) 3 month prior admission Clinical Unit Any use drug abuse within 3 month prior admission Clinical Unit History drink 21 unit alcohol male 14 unit alcohol per week female ( 1 unit = 270 cc beer 40 cc spirit 1 glass wine ) within 3 month prior admission Clinical Unit Positive test drug abuse positive alcohol test screen and/or day admission clinical unit History smoking 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission Clinical Unit Participation clinical study within 3 month participation 3 clinical study within 12 month , prior expect date enrolment study Donation blood blood product within 3 month prior admission Clinical Unit Positive serology test HBsAg , anti HAV ( IgM ) , antiHCV antiHIV 1+2 Subjects , opinion investigator , likely complete trial reason Any clinical condition , , opinion investigator would allow safe completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Cardiography</keyword>
	<keyword>Impedance</keyword>
	<keyword>Age group</keyword>
	<keyword>Gender Identity</keyword>
</DOC>